AgingResearch.NewsJoin free

Ractigen Therapeutics

CompanyChina

Ractigen Therapeutics develops one asset, in phase 1 (RAG-18 in Duchenne muscular dystrophy). Mostly oligonucleotide acting on UTRN; based in China.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • RAG-18

    Small activating RNA (saRNA) targeting and upregulating endogenous utrophin expression.

    Phase 1, Oligonucleotide, UTRN, Duchenne muscular dystrophy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies3

Intelligence